We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Cerebrolysin
An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous.
Prescription medication — not a dietary supplement
Cerebrolysin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Cerebrolysin doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1990–2026 with a typical study size of 442 participants.
Based on 95 studies · 17 meta-analyses · 63 RCTs · 11,728 total participants
Confidence
High confidenceBy outcome
Despite many meta-analyses, the highest-quality Cochrane reviews find no stroke benefit (with a possible harm signal) and only very-low-quality dementia evidence, while positive trials are industry-linked, holding the score emerging.
61 randomised trials
92% were about Cerebrolysin in an audit of 50 of them
Every randomised or controlled trial of Cerebrolysin indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
9 trials ongoing or recruiting · 19 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for Cerebrolysin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Cerebrolysin is a peptidergic drug produced by the controlled enzymatic breakdown of purified pig (porcine) brain proteins, yielding a mixture of low-molecular-weight neuropeptides and free amino acids.
It is given by intramuscular injection or, at higher doses, intravenous infusion, and is promoted as a 'neurotrophic' / 'neuroprotective' agent — the idea being that its peptides mimic endogenous neurotrophic factors (BDNF/GDNF-like activity) to support neuronal survival and neuroplasticity.
It has been approved and is heavily used for decades in Russia, China, and a number of European, post-Soviet and Asian countries for acute ischaemic stroke, vascular and Alzheimer's dementia, and traumatic brain injury.
It is NOT approved by the US FDA and is not a dietary supplement; it is a biological injectable drug, and any non-prescription/grey-market sourcing carries real sterility and identity risks for a pig-tissue-derived product.
The honest evidence picture is mixed-to-disappointing once the highest-quality syntheses are weighed.
The 2020 Cochrane review of acute ischaemic stroke (7 RCTs, 1601 participants) found Cerebrolysin probably makes little or no difference to all-cause death and concluded there was no demonstrated clinical benefit — while flagging moderate-quality evidence of an INCREASE in non-fatal serious adverse events (RR 2.15, 95% CI 1.01-4.55), more pronounced at the higher 30 mL dosing schedule.
The 2019 Cochrane review of vascular dementia (6 RCTs, 597 participants) found a possible cognitive/global-function signal but rated the evidence very-low-quality, noted all the studies had high risk of bias and most were industry-supported, and cautioned that any real effect may be too small to be clinically meaningful.
Against this sit a series of largely industry-linked positive trials and meta-analyses: the CARS / CARS-1+CARS-2 stroke-rehabilitation trials and the CAPTAIN TBI trials report small-to-medium benefits on motor and functional scales; a 2015 meta-analysis suggested benefit in mild-to-moderate Alzheimer's; and TBI meta-analyses report improved GCS/GOS but no mortality benefit.
Even some positive TBI RCTs miss their primary endpoint (a 2023 three-arm rTMS + Cerebrolysin trial showed only non-significant descriptive trends).
The result is a genuinely mixed body of evidence in which the most rigorous, least-conflicted analyses are null-to-negative for the headline indication (acute stroke) and only weak for dementia. Overall evidence is therefore Emerging.
Cerebrolysin is a mixture of porcine-brain-derived neuropeptides and amino acids said to have properties resembling endogenous neurotrophic factors (e.g. BDNF/GDNF), proposed to support neuronal survival and growth. This is the marketed rationale; it is characterised mainly in preclinical work.
Proposed to limit secondary injury cascades (excitotoxicity, neuroinflammation, apoptosis) and to promote neuroplasticity/neurorecovery after ischaemic or traumatic brain injury. Mechanistic claims outrun the human efficacy data, which are mixed.
How Cerebrolysin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
The highest-quality synthesis (Cochrane) shows no benefit and a possible increase in non-fatal serious adverse events — weigh this against the marketing claims.
Not adequately studied — avoid.
Listed as a labelling caution; use only under specialist supervision.
Do not. It is a pig-brain-derived injectable biological; unverified product carries sterility, identity and contamination risk and is not FDA-approved.
Product labelling cautions against combining with MAO inhibitors and certain antidepressants because of additive/summation effects; use only under medical supervision.
Labelling advises against co-administration in the same infusion with balanced amino-acid solutions; an injectable drug to be handled clinically, not stacked like a supplement.
Tip: Cochrane found a possible increase in non-fatal serious adverse events in acute ischaemic stroke, more pronounced at the higher 30 mL schedule — a reason for caution, not a benign profile.
Tip: Administer by a clinician; rotate sites.
Tip: Often linked to too-rapid infusion; slow administration.
Tip: Stop immediately; seek medical care. Risk is inherent to an animal-tissue-derived injectable.
Cerebrolysin has an evidence score of 4/10 — emerging evidence based on 95 indexed studies, including 7 meta-analyses. An injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous. Representative study: PMID 37818733.
Dosing for Cerebrolysin: Trial regimens vary widely (e.g. 30 mL a day IV for 10 days, a schedule in the acute ischaemic stroke trials pooled by the cited Cochrane review, where non-fatal serious adverse events were more frequent than with placebo, and intramuscular injection at lower doses). No validated optimal dose; this is a prescription drug in some countries outside the US, not a self-administered supplement. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Cerebrolysin is in the morning. It can be taken on an empty stomach. Administered by injection (intramuscular at lower doses, intravenous infusion at higher doses) in daily treatment courses (commonly 10-21 days) under medical supervision in the countries where it is approved.
Cerebrolysin should be used with caution — talk to a healthcare provider before taking it. Reported side effects include serious adverse events in a study population, hypersensitivity / allergic reaction (porcine biological), injection-site reactions. How often they occur is not established for all of them. Use caution if any of these apply to you: Known hypersensitivity to the product (porcine-derived biological); Severe renal impairment (status epilepticus and epilepsy are listed cautions in product labelling); Pregnancy / breastfeeding (not adequately studied).
Huperzine A
Too few graded studiesAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Sage
Too few graded studiesA Mediterranean herb with rosmarinic acid and salvianolic compounds that support cognitive function, menopausal symptom relief, and metabolic health through antioxidant and cholinergic mechanisms.
Casein Hydrolysate
Too few graded studiesA milk-derived bioactive peptide — a tryptic hydrolysate of bovine αs1-casein standardized to the decapeptide α-casozepine (Lactium) — marketed for stress, anxiety, and sleep. Honest appraisal: the mechanism is real and food-derived (α-casozepine binds the benzodiazepine site of the GABA-A receptor in vitro), and a handful of small human RCTs show modest reductions in stress symptoms and cortisol plus some sleep-diary improvements. But several trials are industry-linked, two well-designed sleep RCTs were null on their primary endpoint, and effects are small. Well-tolerated; this is an ordinary dietary supplement, not a drug.
Oxytocin
Too few graded studiesA nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 95 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research